COMPASS Pathways plc (CMPS) Stock Profile — Insider Trades & Financials

Net Income-$93.9M

EPS$-2.09

Market Cap$737.4M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Kabir Nath

CEO & Executive Director

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Founded: 2020
Employees: 166
Headquarters: London, W1F 0DQ, United Kingdom

⚡

Core Efficiency

ROE?

177.64%

ROA?

-44.63%

D/E Ratio?

-4.98

📊

Profitability Ratios

Current Ratio?

0.77

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 16, 2026 (in 129 days)

Annual Report (10-K) — Based on filing pattern

Aug 16, 2026

Predicted10-K

Mar 24, 2026

10-KQ4 20257d after period end

Nov 4, 2025

10-QQ3 20255d after period end

Jul 31, 2025

10-QQ2 20253d after period end

May 8, 2025

10-QQ1 20252d after period end

Feb 27, 2025

10-KQ4 20243d after period end

Oct 31, 2024

10-QQ3 20243d after period end

Aug 1, 2024

10-QQ2 20243d after period end

May 8, 2024

10-QQ1 20242d after period end

Loading company sections...

COMPASS Pathways plc

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness